This week, these five stocks have the worst ratings in Sales Growth, one of the eight Fundamental Categories on Portfolio Grader.
Compugen (NASDAQ:CGEN) focuses on the therapeutic proteins and monoclonal antibodies to address unmet needs in the fields of immunology and oncology. CGEN gets F’s in Equity and Cash Flow as well. The price of CGEN is down 35.8% since the first of the year. This is worse than the Nasdaq, which has seen a 14% increase over the same period. For more information, get Portfolio Grader’s complete analysis of CGEN stock.
Sunesis Pharmaceuticals (NASDAQ:SNSS) is a clinical-stage biopharmaceutical Company which focuses on the discovery, development and commercialization of novel small molecule therapeutics for oncology. SNSS gets F’s in Earnings Growth, Earnings Momentum, Analyst Earnings Revisions, Equity, and Cash Flow as well. For more information, get Portfolio Grader’s complete analysis of SNSS stock.
AVEO (NASDAQ:AVEO) engages in discovering, developing, and commercializing targeted cancer therapies using its Human Response Platform. AVEO also gets F’s in Earnings Growth, Earnings Momentum, Equity, Cash Flow, and Operating Margin Growth. The price of AVEO is down 49.6% since the first of the year. For more information, get Portfolio Grader’s complete analysis of AVEO stock.
Navidea Biopharmaceuticals (AMEX:NAVB) is focused on the development and commercialization of precision radiopharmaceutical diagnostics for diseases such as cancer. NAVB also gets an F in Equity. The stock currently has a trailing PE Ratio of 121. For more information, get Portfolio Grader’s complete analysis of NAVB stock.
Aixtron (NASDAQ:AIXG) provides deposition equipment, such as that used in lighting, fiber optic communication systems, and mobile telephone applications, to the semiconductor industry. AIXG gets F’s in Earnings Growth, Earnings Momentum, Analyst Earnings Revisions, and Operating Margin Growth as well. For more information, get Portfolio Grader’s complete analysis of AIXG stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
